β-Dystroglycan Restoration and Pathology Progression in the Dystrophic <i>mdx</i> Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation

β-Dystroglycan Restoration and Pathology Progression in the Dystrophic <i>mdx</i> Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation

ROS-activated cSrc tyrosine kinase (TK) promotes the degradation of β-dystroglycan (β-DG), a dystrophin-glycoprotein complex component, which may reinforce damaging signals in Duchenne muscular dystrophy (DMD). Therefore, cSrc-TK represents a promising therapeutic target. In <i>mdx</i> m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paola Mantuano, Brigida Boccanegra, Elena Conte, Michela De Bellis, Santa Cirmi, Francesca Sanarica, Ornella Cappellari, Ilaria Arduino, Annalisa Cutrignelli, Angela Assunta Lopedota, Antonietta Mele, Nunzio Denora, Annamaria De Luca
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Duchenne muscular dystrophy
preclinical study
<i>mdx</i> mouse
dasatinib
cyclodextrin
oral formulation
Microbiology
QR1-502
Acceso en línea:https://doaj.org/article/68d8ae6534034deeb1e5c4e403792037
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/68d8ae6534034deeb1e5c4e403792037

Ejemplares similares